What the research found

The article surveys four peptides proposed to support physical performance and resilience in active people. hCG is presented as a way to increase endogenous testosterone production modestly in both sexes, with the mechanism being stimulation of natural hormone output rather than exogenous replacement. MOTS-c is framed as a mitochondrial signalling peptide that mimics the recovery signal cells produce after exercise, potentially enhancing aerobic capacity. GH secretagogues (sermorelin, tesamorelin) are described as stimulating the body's own growth hormone release, with claimed benefits for collagen synthesis in connective tissue, sleep, and body composition. GHK-Cu is positioned as a copper peptide with dual effects—established use in skin health but also proposed systemic roles in collagen turnover, inflammation, and neurological function.

The framing emphasizes that these compounds work by amplifying endogenous signals rather than replacing them, and that age-related declines in some (notably GHK-Cu levels) create a rationale for supplementation.

Why it matters for you

If you're tracking testosterone or growth hormone biomarkers on MyKine, these peptides represent an alternative mechanistic approach: rather than direct hormone replacement, they aim to nudge your own production. This could mean less straightforward dose–response tracking but potentially fewer exogenous suppression effects—though the article acknowledges hCG carries HRT-like side effects and GH secretagogues may impair insulin sensitivity, both measurable via your app.

For those logging training stress and recovery metrics, MOTS-c's theoretical link to mitochondrial adaptation and VO2 gains is relevant if you track aerobic performance or HRV. More practically, the connective tissue angle applies directly: if you're managing chronic joint stress, tendon health, or coming back from injury, GHK-Cu and GH secretagogues offer a mechanism-based rationale worth discussing with a physician—collagen synthesis is a genuine biological lever in aging musculoskeletal systems.

The sleep and body composition claims around GH secretagogues are measurable too (sleep tracking, body composition scans), making these testable at the individual level.

Caveats

  • No clinical evidence cited. The piece makes mechanistic arguments but provides no study references, effect sizes, or human trial data—only biological plausibility.
  • Largely theoretical benefits. Claims about MOTS-c endurance gains, GHK-Cu neuroprotection, and GH secretagogue collagen benefits are not grounded in evidence presented here.
  • Side effect warnings incomplete. GH secretagogues' insulin sensitivity impact is flagged, but other potential downsides are minimised or absent.
  • Regulatory status unclear. The article doesn't distinguish between prescription (hCG, GH secretagogues) and research-grade compounds; off-label use carries risks.
  • Individual variation unstated. No mention of how age, sex, baseline hormones, or existing conditions might change risk–benefit.